FDA panel gives unanimous support to Leqembi
The first full regulatory approval for an amyloid-targeting therapy for Alzheimer’s disease could come within a month, after an expert panel voted 6 to 0 in favour of Eisa
Voices to Trials: Engaging Patients in Clinical Trial Design
To improve trial recruitment, engagement, and retention, and to increase the likelihood that trials reflect what matters most to patients, regulatory authorities increasingly point to metho
How to solve a problem like DTx in Europe?
The promise of digital therapeutics (DTx) has been widely discussed and debated since the term first began to emerge back in the early 2010s.
Coaching Never Sleeps
Coaching has developed into one of the most powerful tools in a fast-changing pharmaceutical sector.
Empowering MSLs to be the kings of Pharma’s New Frontier
The demand for high-calibre, sharply-focussed clinical knowledge and data is increasing as HCPs streamline and recalibrate their engagements with the pharmaceutical sector.
3rd Annual iPSC Derived-Cell Therapies Summit
As the iPSC space continues to evolve and candidates move to the clinic, the need to unite with your peers to benchmark the current bottlenecks in discovery, translation and clinical strategy is gr
3rd Rare & Genetic Kidney Disease Drug Development Summit
With the pivotal acceptance of eGFR as a surrogate endpoint along with the advances in genetic therapies and disease pathology sequencing, the floodgates for faster approval and developments in pre